Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medivolve Inc MEDVF

Medivolve Inc. is a Canadian healthcare technology company. The Company and its subsidiaries, Medivolve Pharmacy Inc. (doing business as Marbella Pharmacy) and Kedy Ying Jao D.O., a Medical Corporation, operate a distributed network of two retail patient-care locations in California, United States. It has two business units: Medivolve Pharmacy Division (MPD) and Medivolve Clinic Services Division (MCSD). MPD provides retail pharmacy and mail-order pharmacy services related to COVID-19, antibiotics, dermatology, family medicine, immunology, neurology, pain management, pediatrics, preventive medicine and psychiatry to patients in Southern California. MCSD provides licensed healthcare through a clinic in Brea, California, United States. MCSD is focused on developing a telehealth platform, which connects patients with physicians, and facilitates and manages the provision of virtual consultation, diagnosis, and treatment services in partnership with qualified health practitioners.


OTCPK:MEDVF - Post by User

Post by deepoil0808on Sep 28, 2021 6:01pm
252 Views
Post# 33934694

EXPLOSIVE Growth Revenue +600% overwhelms MEDV

EXPLOSIVE Growth Revenue +600% overwhelms MEDVNumber of tests from June 3, 2021 to July 3, 2021:            5,077/week  at average sales price of:    $ 58 per patient

Number of tests from July 4, 2021 to July 31, 2021          16,794/week  at average sales price of:     150 per patient

Number of tests:  August 1, 2021 to August 15, 2021:      16,794/week at average sales price of:      150 per patient

Numbers of tests: August 16, 2021 to September 28th:    50,382/week at average sales price of:      179 per patient


Under David Preiner, we have exploded 300% in testing rates from June to July 2021 and, another 300% from August 15, 2021 to September 28, 2021.

We can expect under the Biden mandate for testing to explode another 300% to 600% towards 150,000 to 200,000 patients per week. 

Knowscrap brought up an another that MEDV received 20 complaints, some complaining of long lines or delayed results or, not receiving results or discrepancy results.

When you have EXPLOSIVE GROWTH of 600% in 2 months you are going to hit some growing pains as your system is overwhelmed and you need to catch up.   Whatever is off in their system will be adjusted as revenue growth is EXPLOSIVE.

In terms of complaints, it is very low.

20 complaints / (50,392 tests mid August * 6 weeks to end of September)    =    .006 %

That means not even 1/10 of 1%.      It also means that we have 302,332 satisfied patients in a pool of 302,352.

I would call that SPECTACULAR RESULTS 

Target Price:   $ 1.50 per share

Naked shorts are in panic and need to cover, their gig is done.
<< Previous
Bullboard Posts
Next >>